Ameritox, Ltd., Announces Addition of LC-MS-MS
Ameritox, Ltd. (Midland, Texas), a U.S. leader in pain prescription urine drug monitoring, announced its addition of an LC-MS-MS method for detecting prescription pain medications.
Ameritox, Ltd. (Midland, Texas), a U.S. leader in pain prescription urine drug monitoring, announced its addition of an LC-MS-MS method for detecting prescription pain medications.
"We are very pleased to be among the first pain medication monitoring laboratories to invest in this advanced LC-MS-MS multiplexing technology," said Dr. James Bourland, the laboratory director at Ameritox. "By converting two high-volume confirmations from GC-MS to multiplexing LC-MS-MS, Ameritox is able to provide even faster turn-around times as well as the most accurate and reliable analytical results to physician practices, which helps them provide better patient care."
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
Exploring The Chemical Subspace of RPLC: A Data-driven Approach
November 11th 2024Saer Samanipour from the Van ‘t Hoff Institute for Molecular Sciences (HIMS) at the University of Amsterdam spoke to LCGC International about the benefits of a data-driven reversed-phase liquid chromatography (RPLC) approach his team developed.
